CA-SMARTFRAME
13.2.2024 15:15:33 CET | Business Wire | Press release
Truepic, provider of secure content transparency infrastructure, and SmartFrame Technologies, a leading UK-based tech provider that is redefining the digital image standard, have deployed the first secure image protection model that is set to redefine the landscape of authenticity and uncompromised security with provenance in the global sports photography space.
SmartFrame, with its innovative image-streaming technology, has made substantial strides in ensuring the integrity and ownership of media collections. Photos backed by Truepic's trusted certificate authority undergo a seamless and secure verification process that compliantly signs SmartFrame's visual media at scale. Every image is equipped with the Coalition for Content Provenance and Authenticity’s (C2PA) Content Credentials, marking sports brands’ assets as authentic and providing a trusted source of information for online viewers.
Recognizing the importance of ensuring transparency and authenticity online, multiple sports enterprises and brands, such as Six Nations Rugby, New Zealand Rugby, and Manchester City F.C. have embraced SmartFrame’s image-streaming distribution model, supported by Truepic’s certificate authority. These premier sports organizations are elevating global brand protection while simultaneously contributing to a safer and more reliable online image ecosystem within sports photography. Furthermore, by adopting secure image streaming and embedding C2PA Content Credentials, they are setting a benchmark for how digital images are originated, published, consumed, and monetized online. This strategic move aligns with the critical need for enhanced security in the contextual advertising market, projected to reach over $500 billion by 2030, which sports enterprises can take advantage of to help ensure their continued profitability.
“SmartFrame and Truepic’s partnership represents a significant leap forward in digital media integrity,” said Jeffrey McGregor, CEO of Truepic. “SmartFrame’s cutting edge image-streaming network paired with Truepic’s authenticity infrastructure introduces the most efficient way for commercial partners to assure the integrity and ownership of media collections. We are proud to partner with a forward-thinking organization like SmartFrame on industry leading content integrity products.”
"As a fellow member of the C2PA, it's clear that the need for trust, security, and transparency in online visual content is as critical to SmartFrame as it is to Truepic,” explains Rob Sewell, CEO of SmartFrame Technologies. “This shared vision forms the cornerstone of our partnership. By integrating Truepic's widely respected authentication technology into our secure image publishing network, we gain the capability to authenticate images swiftly and effectively, and to provide users with a seamless and trustworthy experience. This collaboration marks the next phase in our mission to provide the highest level of protection and transparency for online content, and we are excited to embark on this journey with a company as esteemed as Truepic."
About Truepic
Truepic provides authenticity infrastructure for the internet. The company’s transparency tools deliver verifiable information about the origin and editing history of digital content. Truepic is dedicated to advancing products and services that establish transparency in digital content, empowering viewers and users to identify authenticity and differentiate human from computer-generated. Recognized as one of TIME’s Best Inventions and Fast Company’s World Changing Ideas, consumers, businesses, creators, and publishers trust Truepic’s technologies to make informed decisions. For more information, visit truepic.com.
About SmartFrame Technologies
Founded in 2015, SmartFrame Technologies is a London-based technology provider whose image streaming platform redefines the standard for online image publishing. It unites sports brands and other content owners with publishers, advertisers, and online audiences, and ensures that images are delivered in the highest quality with maximum security, clear provenance, and detailed analytics. Furthermore, through its contextual ad tech component, brands can reach audiences with high-impact, contextually targeted, in-image advertising and sponsorship placements in a way that recognizes the interests of its viewers and simultaneously complies with global privacy regulations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213285238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
